Step Therapy (Fail-First Policy): Clinical Exception Requests, Medicare 42 CFR § 422.136 & § 423.578 Rules, and Override Workflows

Step therapy—widely known in clinical practice and health policy as a fail-first policy—is a payer utilization management protocol that requires a patient to try and experience documented clinical failure, intolerance, or contraindication on one or more preferred first-line medications (Step 1) before a health plan or pharmacy benefit manager (PBM) will cover a prescribed higher-cost or non-preferred medication (Step 2 or Step 3).

Definition, Scope, and Payer Mechanics

What is step therapy? Within commercial insurance, Medicaid managed care, Medicare Part D prescription drug plans, and Medicare Advantage (Part C) medical benefits, Pharmacy and Therapeutics (P&T) committees organize therapeutic classes into multi-step clinical hierarchies. Unlike inpatient hospital formulary management—which governs which medications a hospital pharmacy stocks for admitted patients under fixed DRG reimbursement—ambulatory step therapy operates as an automated claims-adjudication edit at the retail/specialty pharmacy counter or as a medical-benefit prior authorization gate for clinic-administered infusions.

When a clinician transmits an electronic prescription (via NCPDP SCRIPT) for a Step 2 medication (such as a targeted biologic in rheumatology, a novel oral anticoagulant, or a GLP-1 receptor agonist), the PBM’s adjudication engine runs an automated retrospective claims lookback across the patient’s pharmacy fill history:

• Automated Lookback Pass (Smart Edit): If the payer’s claims database finds a paid prescription claim for the required Step 1 prerequisite drug within the specified lookback window (for example, the preceding 180 or 365 days) for the minimum required trial duration, the Step 2 prescription adjudicates automatically at the pharmacy without manual review.
• Hard Reject and Prior Authorization Trigger: If no qualifying Step 1 claim appears in the payer’s history—either because the patient has never taken the Step 1 drug, or because the patient tried and failed the Step 1 drug while covered under a different insurer or via manufacturer samples—the claim rejects with a step therapy edit, requiring the prescriber to switch to the Step 1 agent or submit a formal step therapy exception request (also termed a step therapy override).

Federal Regulations and Step Therapy Exception Requests (42 CFR § 422.136 & § 423.578)

In federal healthcare programs regulated by the Centers for Medicare & Medicaid Services (CMS), step therapy protocols and step therapy exception criteria are governed by explicit Code of Federal Regulations standards Across Medicare Part D (outpatient prescription drugs) and Medicare Advantage Part B (physician-administered infused or injectable drugs):

1. Medicare Part D Step Therapy Exceptions (42 CFR § 423.578(b))

Under 42 CFR § 423.578(b), a Medicare Part D enrollee, the enrollee’s representative, or the prescribing physician (or other prescriber) may file a formulary tiering or step therapy exception request. The Part D plan sponsor must grant the step therapy exception when the prescriber’s supporting statement demonstrates that the preferred formulary prerequisite drug:

• Has been ineffective in the treatment of the enrollee’s disease or medical condition, OR, based on both sound clinical evidence and medical and scientific evidence and the known relevant physical or mental characteristics of the enrollee and known characteristics of the drug regimen, is likely to be ineffective or adversely affect the drug’s effectiveness or patient compliance; OR
• Has caused or, based on sound clinical evidence, is likely to cause an adverse reaction or other harm to the enrollee.

Under 42 CFR § 423.568 and § 423.572, once the plan receives the prescriber’s supporting statement, it must issue a determination and notify the enrollee and prescriber no later than 72 hours for a standard exception request, or no later than 24 hours for an expedited (urgent) request where waiting the standard timeframe could seriously jeopardize the enrollee’s life, health, or ability to regain maximum function.

2. Medicare Advantage Step Therapy for Part B Drugs (42 CFR § 422.136)

Since 2019, CMS has permitted Medicare Advantage (MA) plans to apply step therapy to Part B physician-administered medications under strict statutory guardrails codified in 42 CFR § 422.136:

• New Administrations Only (365-Day Lookback Rule): Under 42 CFR § 422.136(a)(1), step therapy may not disrupt ongoing Part B drug therapies for enrollees. MA plans must use a lookback period of 365 days to verify whether the enrollee has actively received the Part B medication; if the patient received the drug within the past 365 days, step therapy cannot be imposed.
• P&T Committee Clinical Review: Under § 422.136(b), step therapy policies must be reviewed and approved by a Pharmacy and Therapeutics committee that includes practicing physicians and pharmacists meeting the conflict-of-interest and clinical-evidence requirements of 42 CFR § 423.120(b).
• Drug-to-Drug Stepping Rules: Under § 422.136(a)(3), an MA plan may require an enrollee to try another Part B drug, or a Part D drug (if the MA plan is an MA-PD plan offering Part D coverage), before covering the requested Part B drug, provided the step-therapy prerequisite drug is supported by FDA-approved labeling or Medicare-recognized compendia for that indication.
• Adjudication Timelines: Part B drug pre-service organization determinations and step therapy exception requests are bound by the shortened Part B drug timelines in 42 CFR §§ 422.568(b)(2) and 422.572(a)(2): 72 hours for standard requests and 24 hours for expedited requests (with no extensions permitted).

Types of Step Therapy Overrides and State Step Therapy Laws

Across state-regulated commercial health plans (regulated by state departments of insurance) and federal Medicare/Medicaid rules, step therapy laws by state establish standardized clinical override pathways. While self-funded employer health plans governed by federal ERISA (Employee Retirement Income Security Act of 1974) are generally preempted from state insurance mandates unless federal legislation applies, state step therapy statutes and CMS regulations recognize five primary clinical criteria for a step therapy override:

Override / Exception Criterion	Clinical Justification Required in Prescriber Statement	Required EHR Source Documentation	Typical Regulatory Basis
1. Prior Trial and Failure	Patient previously completed an adequate trial of the Step 1 drug (including under a prior insurer or via clinic samples) without achieving therapeutic target	Prior clinic progress notes, pharmacy dispense history, lab/disease-activity scores before and after Step 1 trial	42 CFR § 423.578(b)(5)(i); state fail-first override statutes
2. Contraindication or Drug-Drug Interaction	The required Step 1 agent is contraindicated per FDA-approved prescribing information or creates a severe drug-disease or drug-drug interaction	Active problem list (ICD-10), renal/hepatic lab panels (eGFR, AST/ALT), concomitant medication list	42 CFR § 423.578(b)(5)(ii); FDA package insert Boxed Warnings / Contraindications
3. Expected Ineffectiveness Based on Patient Characteristics	Biomarker, genotype, disease stage, or anatomical phenotype demonstrates that the Step 1 mechanism of action is clinically inappropriate	Pathology/molecular diagnostics report (e.g., mutation status), severity staging score, peer-reviewed guideline citation	42 CFR § 423.578(b)(5)(i) (“likely to be ineffective”)
4. History of Intolerance or Adverse Event	Patient previously experienced a documented adverse drug reaction (ADR) or toxicity to the Step 1 agent or its pharmacologic class	EHR allergy/intolerance module entry with specific reaction date and clinical manifestation	42 CFR § 423.578(b)(5)(ii)
5. Continuity of Care / Stable on Current Therapy	Patient is already clinically stable on the target Step 2 medication (initiated under a prior health plan, inpatient admission, or prior authorization)	Outpatient medication reconciliation record (BPMH workflow) and recent fill/infusion dates	42 CFR § 422.136(a)(1) (365-day Part B lookback); state continuity-of-care statutes

Where Step Therapy Matters in Clinical Research and Health Informatics

How is step therapy used in clinical research and healthcare? Beyond routine outpatient clinic operations, step therapy intersects directly with clinical trial design, observational pharmacoepidemiology, and EHR interoperability:

• Clinical Trial Eligibility Criteria (Treatment-Refractory Cohorts): Phase II and Phase III clinical trials in oncology, autoimmune diseases (rheumatoid arthritis, inflammatory bowel disease, psoriasis), and neurology routinely mirror payer step therapy hierarchies in their protocol inclusion criteria—requiring documented failure of or intolerance to at least one conventional synthetic disease-modifying antirheumatic drug (csDMARD) or first-line standard-of-care agent prior to enrollment. Research coordinators screening patients must extract the exact dates, dosages, and discontinuation reasons (lack of efficacy vs. toxicity) for prior step therapies into the electronic case report form (eCRF).
• Confounding by Indication in Real-World Evidence (RWE): In retrospective EHR and claims cohort studies (such as MarketScan or Medicare claims analyses), step therapy rules create structural channelling bias: patients receiving a second-line drug in routine care have, by regulatory definition, already failed a first-line agent and therefore have longer disease duration or higher baseline severity than treatment-naive patients. Pharmacoepidemiologists must account for step-therapy line of therapy using active-comparator new-user designs and propensity score weighting.
• EHR Real-Time Benefit Check (RTBC) and Electronic Prior Authorization (ePA): Modern EHRs integrate NCPDP Real-Time Prescription Benefit (RTPB) transactions and HL7 FHIR Da Vinci Coverage Requirements Discovery (CRD) / Prior Authorization Support (PAS) APIs. When a clinician orders a medication, the EHR displays whether a step therapy edit applies and allows automated extraction of prior medication failures and ICD-10 diagnoses into an electronic step therapy exception request. See prior authorization vs. precertification and utilization review in healthcare for how pre-service pharmacy edits differ from inpatient medical necessity reviews.

Common Misunderstandings in Clinic Operations

• Misunderstanding 1: “Trying a drug via clinic samples or a prior insurer automatically satisfies the PBM’s step edit.” Automated pharmacy claims engines can only see prescription fills paid by that specific payer or PBM. If a patient failed Step 1 two years ago under a different employer plan or via free physician samples, the PBM’s automated lookback will reject the Step 2 claim at the pharmacy counter. The clinic must submit a manual or electronic step therapy exception request documenting the historical trial dates in the chart notes.
• Misunderstanding 2: “Step therapy and prior authorization are mutually exclusive.” Step therapy is a specific clinical logic subset of prior authorization. Many specialty drugs require both clinical criteria verification (such as a confirmed diagnostic lab threshold) AND step therapy verification (documented failure of a preferred generic or biosimilar).

Frequently Asked Questions

What is step therapy?

Step therapy—commonly called a “fail-first policy”—is a health plan and pharmacy benefit manager (PBM) utilization management protocol that requires a patient to try and clinically fail one or more payer-preferred, lower-cost first-line medications (Step 1) before the plan will authorize coverage for a prescribed second-line or non-preferred therapy (Step 2).

How is step therapy used in clinical research and healthcare?

In healthcare operations, step therapy is enforced at point-of-sale pharmacy adjudication or through medical-benefit prior authorization to steer utilization toward generics, biosimilars, or preferred formulary agents. In clinical research, prior failure of step-therapy-mandated first-line agents frequently serves as an inclusion criterion for Phase II/III refractory disease trials, while real-world evidence (RWE) and health economics studies analyze treatment switching, non-medical switching, and time-to-therapy delays caused by fail-first edits.

Sources

• Code of Federal Regulations — 42 CFR § 422.136 (Medicare Advantage Step Therapy for Part B Drugs) (https://www.law.cornell.edu/cfr/text/42/422.136).
• Code of Federal Regulations — 42 CFR § 423.578 (Medicare Part D Exceptions Procedures: Tiering and Step Therapy Exceptions) (https://www.law.cornell.edu/cfr/text/42/423.578).
• Centers for Medicare & Medicaid Services (CMS) — CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F) Fact Sheet and Electronic Prior Authorization Standards (https://www.cms.gov/newsroom/fact-sheets/cms-interoperability-and-prior-authorization-final-rule-cms-0057-f).